We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals

100 hedge funds and large institutions have $227M invested in Rigel Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 35 increasing their positions, 30 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more call options, than puts

Call options by funds: $444K | Put options by funds: $293K

42% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 12

17% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 30

5% more funds holding

Funds holding: 95100 (+5)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

24% less capital invested

Capital invested by funds: $300M → $227M (-$73.5M)

Holders
100
Holders Change
+5
Holders Change %
+5.26%
% of All Funds
2.9%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
17
Increased
35
Reduced
30
Closed
12
Calls
$444K
Puts
$293K
Net Calls
+$151K
Net Calls Change
-$421K
Name Holding Trade Value Shares
Change
Change in
Stake
TA
51
Teachers Advisors
New York
$377K +$40.1K +1,367 +12%
USAA
52
United Services Automobile Association
Texas
$346K
PAAMCP
53
Pacific Alternative Asset Management Company (PAAMCO)
California
$346K +$356K +12,139 New
RhumbLine Advisers
54
RhumbLine Advisers
Massachusetts
$343K -$22.6K -770 -6%
SAM
55
Senzar Asset Management
New York
$341K +$351K +11,970 New
SCA
56
Secor Capital Advisors
New York
$312K +$321K +10,945 New
VOYA Investment Management
57
VOYA Investment Management
Georgia
$270K
Jane Street
58
Jane Street
New York
$236K +$108K +3,665 +79%
State Board of Administration of Florida Retirement System
59
State Board of Administration of Florida Retirement System
Florida
$234K
PPA
60
Parametric Portfolio Associates
Washington
$221K +$111K +3,780 +95%
Swiss National Bank
61
Swiss National Bank
Switzerland
$215K
MLICM
62
Metropolitan Life Insurance Company (MetLife)
New York
$209K
NFA
63
Nationwide Fund Advisors
Ohio
$194K -$3.35K -114 -2%
BA
64
BlackRock Advisors
Delaware
$169K +$17.9K +609 +11%
AIG
65
American International Group
New York
$165K -$1.7K -58 -1%
California Public Employees Retirement System
66
California Public Employees Retirement System
California
$151K -$10.3K -350 -6%
DekaBank Deutsche Girozentrale
67
DekaBank Deutsche Girozentrale
Germany
$135K +$2.94K +100 +2%
PP
68
Paloma Partners
Connecticut
$130K -$56.2K -1,916 -30%
ProShare Advisors
69
ProShare Advisors
Maryland
$128K -$120K -4,097 -48%
Citigroup
70
Citigroup
New York
$127K +$22.6K +769 +21%
PL
71
Parkwood LLC
Ohio
$116K +$119K +4,065 New
WMSA
72
Weiss Multi-Strategy Advisers
New York
$113K +$116K +3,968 New
Public Employees Retirement Association of Colorado
73
Public Employees Retirement Association of Colorado
Colorado
$109K
DS
74
DRW Securities
Illinois
$108K +$8.92K +304 +9%
WAM
75
Wolverine Asset Management
Illinois
$88K +$91K +3,100 New

RIGL Hedge Fund Activity: Q4 2013 in Review

100 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2013, worth a combined $227M — down 24% from $300M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new RIGL positions and 12 closed out — a net gain of 5 holders — while 35 added to existing stakes and 30 trimmed.

The largest buyer was Visium Asset Management, opening a new position worth an estimated $5.9M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $16.5M sold.

  • 100 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2013, up from 95 in Q3 2013.
  • Funds reported $227M of Rigel Pharmaceuticals stock for Q4 2013, down 24% quarter-over-quarter.
  • 17 funds opened new Rigel Pharmaceuticals positions in Q4 2013 and 12 closed out, a net change of +5 holders.
  • The largest Rigel Pharmaceuticals buyer in Q4 2013 was Visium Asset Management, an estimated $5.9M added.
  • The largest Rigel Pharmaceuticals seller in Q4 2013 was T. Rowe Price Associates, an estimated $16.5M sold.

Based on aggregated 13F filings for Q4 2013.